跳至主要内容
临床试验/NCT01016470
NCT01016470已完成3 期

Efficacy of Nutritional Supplement VIUSID/ALZER in Patients With Parkinson's Disease

Catalysis SL1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2009年10月最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
Catalysis SL
入组人数
100
试验地点
1
主要终点
Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)

研究概览

简要总结

The purpose of the study is to evaluate whether Viusid/Alzer Nutritional supplements, could improve the progression disease, in patients with Parkinson's Disease (PD).

详细描述

Periodical measures of the clinical features with UPDRS will be done at the beginning, each three months until two years. Each group will be compare to evaluate.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
20 Years 至 90 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients with clinical of PD, with the criteria of Brain Bank of London with early stage.
  • Informed consent.

排除标准

  • Presence of another disease not well controlled.
  • Patient with atypical features.
  • Patient with advanced Parkinson's disease.

结局指标

主要结局

Periodical measures of the clinical features with Unified Parkinson Disease Rating Scale (UPDRS) will be done at the beginning, every three months until one year (end of the treatment)

时间窗: one year

次要结局

  • Hoehn-Yarh will be done at the beginning, every three months until one year (end of the treatment)(one year)
  • Dosage levodopa will be done at the beginning, every three months until one year (end of the treatment)(one year)

研究者

发起方
Catalysis SL
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验